NO20091191L - Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme - Google Patents
Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de sammeInfo
- Publication number
- NO20091191L NO20091191L NO20091191A NO20091191A NO20091191L NO 20091191 L NO20091191 L NO 20091191L NO 20091191 A NO20091191 A NO 20091191A NO 20091191 A NO20091191 A NO 20091191A NO 20091191 L NO20091191 L NO 20091191L
- Authority
- NO
- Norway
- Prior art keywords
- vitamin
- cancer
- additional therapeutic
- therapeutic agent
- methods
- Prior art date
Links
- 229930003316 Vitamin D Natural products 0.000 title abstract 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 235000019166 vitamin D Nutrition 0.000 title abstract 3
- 239000011710 vitamin D Substances 0.000 title abstract 3
- 229940046008 vitamin d Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003710 vitamin D derivatives Chemical class 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- -1 vitamin D compound Chemical class 0.000 abstract 2
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93492406P | 2006-08-25 | 2006-08-25 | |
| PCT/US2007/018770 WO2008024485A2 (en) | 2006-08-25 | 2007-08-23 | Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20091191L true NO20091191L (no) | 2009-03-23 |
Family
ID=39107444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20091191A NO20091191L (no) | 2006-08-25 | 2009-03-20 | Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP2063963A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010501576A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090060306A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101528309A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007287099A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2661546A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL197212A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20091191L (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008024485A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170434A (es) * | 2009-01-27 | 2017-11-21 | Berg Llc | VITAMINA D3 Y ANALOGOS DE LA MISMA PARA ALIVIAR EFECTOS SECUNDARIOS ASOCIADOS CON LA QUIMIOTERAPIA. (Divisional 2011-0445) |
| KR101360725B1 (ko) | 2009-06-26 | 2014-02-07 | 노파르티스 아게 | Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체 |
| WO2011007208A1 (en) * | 2009-07-16 | 2011-01-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compounds and methods for the treatment of cancer |
| EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| US20120116381A1 (en) | 2010-11-05 | 2012-05-10 | Houser Kevin L | Surgical instrument with charging station and wireless communication |
| JP6002210B2 (ja) | 2011-04-28 | 2016-10-05 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| US9801844B2 (en) * | 2012-05-24 | 2017-10-31 | The Research Foundation Of The City University Of New York | Methods and compositions for the treatment of cancer |
| EA030128B1 (ru) | 2012-09-26 | 2018-06-29 | Арагон Фармасьютикалз, Инк. | Способ лечения неметастатического кастрационно-резистентного рака простаты |
| WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| MX2015014701A (es) | 2013-04-24 | 2016-08-08 | Salk Inst For Biological Studi | Circuito genomico del receptor de vitamina d/smad que regula la compuerta de la respuesta fibrotica. |
| EP3473299A1 (en) | 2013-06-05 | 2019-04-24 | Salk Institute for Biological Studies | Vitamin d receptor agonists to treat diseases involving cxcl12 activity |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120722A (en) | 1984-02-08 | 1992-06-09 | Hoffmann-La Roche Inc. | Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia |
| US4857518A (en) | 1984-10-04 | 1989-08-15 | Wisconsin Alumni Research Foundation | Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same |
| US4717721A (en) | 1985-05-30 | 1988-01-05 | Howard W. Bremer | Sidechain homo-vitamin D compounds with preferential anti-cancer activity |
| US4866048A (en) | 1985-08-02 | 1989-09-12 | Leo Pharmaceutical Products Ltd. | Novel vitamin D analogues |
| US5145846A (en) | 1988-01-20 | 1992-09-08 | Hoffmann-La Roche Inc. | Vitamin D3 analogs |
| US4851401A (en) | 1988-07-14 | 1989-07-25 | Wisconsin Alumni Research Foundation | Novel cyclopentano-vitamin D analogs |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| GB8915770D0 (en) | 1989-07-10 | 1989-08-31 | Leo Pharm Prod Ltd | Chemical compounds |
| DE4101953A1 (de) | 1991-01-19 | 1992-07-23 | Schering Ag | 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel |
| DE4141746A1 (de) | 1991-12-13 | 1993-06-17 | Schering Ag | 20-methyl-substituierte vitamin d-derivate |
| DE69327096T2 (de) * | 1992-03-31 | 2000-06-21 | Btg International Ltd., London | 17-substituierte steroide, verwendbar bei behandlung von krebs |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5547947A (en) | 1993-03-11 | 1996-08-20 | Hoffmann-La Roche Inc. | Methods of treatment |
| GB9622590D0 (en) | 1996-10-30 | 1997-01-08 | Leo Pharm Prod Ltd | Chemical compounds |
| US6521608B1 (en) | 1998-03-27 | 2003-02-18 | Oregon Health & Science University | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders |
| EP1276482B1 (en) * | 2000-03-02 | 2008-01-16 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Combination chemotherapy |
| US7094775B2 (en) * | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
-
2007
- 2007-08-23 JP JP2009525648A patent/JP2010501576A/ja active Pending
- 2007-08-23 CA CA002661546A patent/CA2661546A1/en not_active Abandoned
- 2007-08-23 CA CA2838089A patent/CA2838089A1/en not_active Abandoned
- 2007-08-23 WO PCT/US2007/018770 patent/WO2008024485A2/en not_active Ceased
- 2007-08-23 CN CNA2007800385939A patent/CN101528309A/zh active Pending
- 2007-08-23 EP EP07837327A patent/EP2063963A2/en not_active Withdrawn
- 2007-08-23 AU AU2007287099A patent/AU2007287099A1/en not_active Abandoned
- 2007-08-23 KR KR1020097005973A patent/KR20090060306A/ko not_active Withdrawn
- 2007-08-23 EP EP11175046.9A patent/EP2425874A3/en not_active Withdrawn
-
2009
- 2009-02-24 IL IL197212A patent/IL197212A0/en unknown
- 2009-03-20 NO NO20091191A patent/NO20091191L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008024485A2 (en) | 2008-02-28 |
| AU2007287099A1 (en) | 2008-02-28 |
| CA2838089A1 (en) | 2008-02-28 |
| CA2661546A1 (en) | 2008-02-28 |
| JP2010501576A (ja) | 2010-01-21 |
| EP2063963A2 (en) | 2009-06-03 |
| KR20090060306A (ko) | 2009-06-11 |
| WO2008024485A3 (en) | 2009-03-05 |
| EP2425874A3 (en) | 2013-05-15 |
| EP2425874A2 (en) | 2012-03-07 |
| CN101528309A (zh) | 2009-09-09 |
| IL197212A0 (en) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20091191L (no) | Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme | |
| CY1125077T1 (el) | Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3 | |
| BR112021022897A2 (pt) | Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo | |
| MX380318B (es) | Nanoparticula que comprende rapamicina y albumina como agente anticancer. | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
| BR112012024442A2 (pt) | métodos de tratamento de câncer | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| NO20064584L (no) | Tetrahydropyridoindolderivater | |
| CL2008001839A1 (es) | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. | |
| WO2008082602A3 (en) | Compounds and pharmaceutical compositions for the treatment of liver disorders | |
| CY1107906T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου | |
| MX2009011533A (es) | Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas. | |
| WO2012027065A3 (en) | Combination therapy for treatment of disease | |
| NO20064054L (no) | Terapeutiske kombinasjoner av atypiske antipsykotika med corticotropine frigivningsfaktor antagonister | |
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| WO2007097989A3 (en) | A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer | |
| WO2012096718A3 (en) | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance | |
| NO341574B1 (no) | Forbindelse, farmasøytisk sammensetning og sett for behandling av cancer eller i en avbildningsmetode. | |
| WO2014160216A3 (en) | Dual targeting anticancer agents | |
| WO2008116161A3 (en) | Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states | |
| ZA202301066B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| SE0400346D0 (sv) | Steroids for cancer treatment | |
| SE0401871D0 (sv) | New compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |